Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vbi Vaccines Inc CS
(NQ:
VBIV
)
0.0653
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vbi Vaccines Inc CS
< Previous
1
2
3
4
5
6
7
Next >
VBI Vaccines' Brain Cancer Immunotherapy Gets FDA Fast Track Review; Announces Updated Tumor Response, Overall Survival Data
June 08, 2021
The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ: VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat...
Via
Benzinga
Exposures
Product Safety
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
June 08, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
June 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%
May 22, 2021
The integration of technology and successful clinical trials for treating critical ailments have boosted Wall Street’s optimism about several biotech stocks. Analysts expect Bionano, Cerus, Agenus and...
Via
Talk Markets
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
VBI Vaccines Secures $12M In Second Tranche of Debt Financing With K2 HealthVentures
May 21, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced an agreement to draw down a $12 million second tranche under its previously announced debt financing facility with K2...
Via
Benzinga
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
May 21, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
May 20, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
May 12, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate...
Via
Benzinga
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
May 12, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 03, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
April 28, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
April 27, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research
April 26, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
April 21, 2021
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient...
Via
Benzinga
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21, 2021
From
Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
April 12, 2021
From
VBI Vaccines Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.